Xencor Inc
Research Xencor Inc (XNCR) on Bullrun: market cap USD 2.18B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXNCR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.18B
- Financial periodQ2 2026
- RevenueUSD 51.22M
- Net income-USD 21.73M
- Free cash flow-USD 56.20M
Valuation Snapshot
latest market cap is USD 2.18B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 125.58M | -USD 91.92M | -USD 138.27M | n/a | -1.24 | USD 54.07M | USD 119.75M | USD 635.59M |
| FY2024 | USD 110.49M | -USD 232.62M | -USD 208.29M | n/a | -3.58 | USD 40.88M | USD 163.61M | USD 677.61M |
| FY2023 | USD 174.62M | -USD 133.13M | -USD 96.37M | n/a | -2.2 | USD 53.79M | USD 189.48M | USD 661.75M |
| FY2022 | USD 164.58M | -USD 55.18M | -USD 14.01M | n/a | -0.93 | USD 53.94M | USD 0 | USD 727.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.18B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.10B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.61B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.29B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.56B | 54.3 | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.38B | 29.7 | n/a | n/a |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xencor Inc's market cap?
Xencor Inc's market capitalization is USD 2.18B.
What does Xencor Inc do?
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.